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Background. Although human immunodeficiency virus (HIV) infection is an established risk factor for several bacterial infec-
tions, the association between HIV infection and meningococcal disease remains unclear.
Methods. Expanded chart reviews were completed on persons with meningococcal disease and HIV infection reported from 
2000 through 2008 from 9 US sites participating in an active population-based surveillance system for meningococcal disease. 
The incidence of meningococcal disease among patients meeting Centers for Disease Control and Prevention acquired immune 
deficiency syndrome (AIDS) surveillance criteria was estimated using data from the National HIV Surveillance System for the par-
ticipating sites.
Results. Thirty-three cases of meningococcal disease in individuals with HIV infection were reported from participating sites, 
representing 2.0% of all reported meningococcal disease cases. Most (75.8%) persons with HIV infection were adult males aged 25 
to 64 years old. Among all meningococcal disease cases aged 25 to 64 years old, case fatality ratios were similar among HIV-infected 
and HIV-uninfected persons (13.3% vs 10.6%; P = .6). The cumulative, mean incidence of meningococcal disease among patients 
aged 25 to 64 years old with HIV infection ever classified as AIDS was 3.5 cases per 100 000 person years (95% confidence interval 
[CI], 2.1–5.6), compared with 0.3 cases per 100 000 person years (95% CI, 0.3–0.3) for persons of the same age group not reported 
to have AIDS (relative risk = 12.9; 95% CI, 7.9–20.9).
Conclusions. Individuals with HIV infection meeting the AIDS surveillance case definition have a higher incidence of meningo-
coccal disease compared with the general adult population.
Keywords.  disease surveillance; HIV; meningitis; meningococcal disease.
Although it is well established that individuals with human 
immunodeficiency virus (HIV) infection are at increased risk 
of several bacterial infections, including invasive pneumococ-
cal disease [1], the association between Neisseria meningitidis 
infection and HIV infection is less clear. Like Streptococcus 
pneumoniae and Haemophilus influenzae, N meningitidis is an 
encapsulated bacterial pathogen that is normally an upper air-
way commensal, and systemic infections with these bacteria are 
associated with asplenia and complement deficiencies [2, 3]. 
Individuals with terminal complement deficiencies are at par-
ticularly elevated risk of invasive meningococcal infection [3].
Previous studies examining the association between HIV 
infection and meningococcal disease have produced conflicting 
results. Although some case series and studies from industri-
alized countries have suggested an increased risk of menin-
gococcal infection in persons with HIV, early studies were 
limited by small numbers of patients [4–6]. In contrast, most 
reports from Africa have not shown an association [7–10]. 
Most recently, studies from South Africa [11], New York City 
[12], and England [13] with larger case numbers have reported 
elevated relative risks of meningococcal disease among HIV-
infected individuals. Clinical data describing meningococcal 
disease in HIV-infected patients are also limited, although the 
South African study found HIV infection to be a risk factor for 
meningococcal bacteremia [11].
A better understanding of the association between HIV 
infection and meningococcal disease is important to inform 
prevention strategies. In this study, we reviewed cases of menin-
gococcal disease in patients with diagnosed HIV infection 
M A J O R  A R T I C L E
Received 22 August 2016; accepted 20 October 2016.
Correspondence: Henry M.  Wu, MD, Emory University, 550 Peachtree Street NE, MOT 7, 
Atlanta, GA 30308 (hmwu@emory.edu).
Open Forum Infectious Diseases®
Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2016. 
This work is written by (a) US Government employee(s) and is in the public domain in the US.
DOI: 10.1093/ofid/ofw226
2 • OFID • Harris et al
reported through a population-based surveillance system for 
meningococcal disease [14, 15] and estimated the incidence of 
meningococcal disease in persons with HIV ever classified as 
stage 3, acquired immune deficiency syndrome (AIDS).
METHODS
Meningococcal Disease Surveillance
Surveillance of N meningitidis invasive infection was con-
ducted through the Active Bacterial Core surveillance sys-
tem (ABCs), part of the Centers for Disease Control and 
Prevention (CDC)’s Emerging Infections Program [14, 15]. 
The ABCs is an active, laboratory- and population-based 
surveillance system with sites in 10 states. The surveillance 
area included California (3 San Francisco Bay area counties), 
Colorado (5 Denver area counties), Connecticut, Georgia, 
Maryland, Minnesota, New Mexico (2004–2008), New 
York (15 Rochester and Albany area counties), Oregon, and 
Tennessee (11 Nashville, Chattanooga, and Knoxville coun-
ties). The population under surveillance was approximately 
35 559 550 in 2008, representing 11.7% of the US population 
in 2008. A case of meningococcal disease was defined as the 
isolation of N meningitidis from a normally sterile site such 
as blood, cerebrospinal fluid, pleural fluid, or joint fluid in 
a resident of an ABCs catchment area. Neisseria meningitidis 
isolates were sent to state public health laboratories for sero-
group determination and to the CDC Meningitis Laboratory 
for testing with serogroup-specific real-time polymerase 
chain reaction assays [16].
Chart Review
Chart reviews are routinely performed on all meningococ-
cal disease cases to collect demographic and clinical data. 
Surveillance officers record HIV infection as a comorbid con-
dition on the case report form if it is reported in the hospital 
record. For this study, meningococcal disease cases with onset 
dates from January 1, 2000 until December 31, 2008 in ABCs 
sites were included. Cases reported from the New York ABCs 
site were excluded due to local health information disclosure 
policies pertaining to HIV infection. Cases were also excluded 
from the Colorado site if reported from 2000 (due to incom-
plete data for that year since this site began participation in 
ABCs during 2000)  and the Maryland site if reported from 
2000 (because data on comorbid medical conditions were not 
reported by this site until after that year).
Expanded chart reviews were performed on persons with 
diagnosed HIV infection using a supplemental case report 
form, which included information on HIV disease-re-
lated data (eg, CD4 cell counts, AIDS-defining conditions, 
medications to treat HIV and for opportunistic infection 
chemoprophylaxis), meningococcal disease risk factors, 
comorbid conditions, meningococcal vaccination history, 
physical examination at presentation, hospital course, and 
complications. Data for the expanded chart reviews were 
abstracted from the inpatient hospital record for the episode 
of meningococcal disease; data from the patient’s primary 
care clinic records also were included if available. Human 
immunodeficiency virus infection was classified as meeting 
the CDC AIDS surveillance case definition if data from the 
expanded chart review indicated a CD4 count ever less than 
200 cells/µL and/or a history of an AIDS-defining condition 
[17]. A concurrent CD4 cell count was defined as a CD4 count 
dated within 3 months before the date of meningococcal dis-
ease presentation, performed during the hospitalization, or 
reported in the chart as current.
Analysis
Among meningococcal disease cases ages 25 to 64  years, 
clinical and microbiologic characteristics of those with diag-
nosed HIV infection were compared with those without HIV 
infection using the Fisher’s exact test for categorical data and 
the Wilcoxon-Mann-Whitney test for continuous variables. 
Analyses of younger and older age groups were not possi-
ble due to the paucity of HIV-infected patients outside this 
age range.
Determination of meningococcal disease incidence 
among all HIV-infected individuals was not possible due to 
the absence of name-based HIV reporting in all states dur-
ing the study years. Therefore, the cumulative, annual inci-
dence of meningococcal disease among individuals aged 25 
to 64 years with HIV infection that met the CDC AIDS sur-
veillance case definition [17] was estimated. The number of 
persons with meningococcal disease and a history of a CD4 
count less than 200 cells/µL or a history of an AIDS-defining 
condition was used as the numerator, and end-year AIDS case 
counts reported to CDC’s National HIV Surveillance System 
for ABCs counties were used as the denominator. Because of 
increased levels of AIDS-defining condition ascertainment 
resulting from our chart review when compared with routine 
HIV surveillance (where most cases meet AIDS surveillance 
criteria with CD4 count criteria [17, 18]), a second incidence 
estimate was made including only HIV-infected meningococ-
cal disease patients aged 25 to 64 years with a CD4 count ever 
<200 cells/µL in the numerator (excluding patients staged with 
only a history of an AIDS-defining condition). The cumulative 
annual incidence of meningococcal disease among patients 
aged 25 to 64 years that did not meet AIDS surveillance cri-
teria was also estimated. For this calculation, the number of 
meningococcal disease cases with no HIV infection reported 
to ABCs or HIV infection reported but data from expanded 
chart review did not fulfill CDC AIDS surveillance criteria 
was used as the numerator. The denominator was the popula-
tion of the study area that was not reported with AIDS, which 
was calculated by subtracting the number of end-year AIDS 
case counts reported to the CDC from the total population 
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for the ABCs counties based on US Census data. Confidence 
intervals (CIs) were calculated based on Jeffreys Prior method 
for incidence estimates and Mantel-Haenszel interval esti-
mates for rate ratios.
All statistical analyses were conducted using SAS 9.3 (SAS 
Institute Inc., Cary, NC). Two-sided P values less than 0.05 
were considered significant. This study was determined to be 
nonhuman subjects research, exempt from human subjects 
regulations by the CDC Human Research Protection Office. 
The study was also determined exempt from human subjects 
regulations by the participating ABCs surveillance sites except 
for the Georgia Metropolitan Statistical Area (MSA) and 
Maryland sites. The study was approved by the investigational 
review boards of the Georgia MSA, Maryland Department 
of Health and Mental Hygiene, and Johns Hopkins School of 
Public Health.
RESULTS
During the study period, 1613 cases of meningococcal dis-
ease were reported. Thirty-three (2.0%) of these patients had 
a reported diagnosis of HIV infection. The median ages of 
HIV-infected patients and those without HIV infection were 
41 years (range, 15–60) and 20.5 years (range, 0–98), respec-
tively. Among patients aged 25 to 64  years, there were 491 
meningococcal disease cases, 30 (6.1%) of whom had HIV 
infection reported (Table  1). In this age group, case fatality 
ratios were similar among HIV-infected and HIV-uninfected 
persons (13.3% vs 10.6%, P = .6). Other clinical characteristics, 
including meningococcal disease syndrome, and N mening-
itidis serogroups were similar among those with and without 
reported HIV infection, except a higher proportion of HIV-
infected persons were male compared with persons without 
HIV infection (83.3% vs 51.4%, P = .0007).
Expanded chart reviews were completed for 32 of the 33 
persons with HIV infection (97.0%). Comorbid conditions, 
physical examination findings, complications, and HIV-related 
clinical data are summarized in Table 2. Two patients had ini-
tially been suspected to have disseminated Neisseria gonor-
rhoeae infection based on clinical findings, including 1 with 
septic arthritis. Eighteen patients had infection that met the 
AIDS surveillance case definition, including 10 (55.6%) who 
had a history of a CD4 count <200 cells/µL found on chart 
review and 8 (44.4%) who met surveillance criteria based on a 
Table 1. Clinical and Microbiologic Characteristics of Patients With and 
Without Reported HIV Infection, Aged 25–64, 2000–2008, in Active Bacterial 
Core Surveillance Sitesa 
Patient Characteristics
HIV-Infected 
(N = 30)
No HIV Infection  
Reported (N = 461)
Male, n (%)b 25 (83.3) 237 (51.4)
Median age (years) 44.5 44.0
Case fatality ratio (%) 13.3 10.6
Syndrome
 Meningitis, n (%) 11 (36.7) 238 (52.8)
 Bacteremia, n (%) 11 (36.7) 140 (31.0)
 Bacteremic pneumonia, n (%) 7 (23.3) 51 (11.3)
 Other, n (%) 1 (3.3)c 22 (4.9)
Neisseria meningitidis serogroup
 B, n (%) 7 (25.0) 142 (33.3)
 C, n (%) 11 (39.3) 134 (31.5)
 Y, n (%) 8 (28.6) 139 (32.6)
 W, n (%) 2 (7.1) 11 (2.6)
Abbreviations: HIV, human immunodeficiency virus.
aDenominators may vary due to missing data. P values for all comparisons >.05 unless 
otherwise noted.
bFisher’s exact P = .0007.
cSeptic arthritis.
Table  2. Clinical Data of HIV-Infected Persons With Meningococcal 
Disease Reported by Active Bacterial Core Surveillance Sites, 2000–2008 
(n = 32)a
Clinical Characteristics N (%)
Past Medical History, Physical Exam on Admission, and Complications
History Previous meningococcal vaccination 0
Tobacco use 11 (35.5)
Asplenia 1 (3.1)
Complement deficiency 0
Diabetes mellitus 3 (9.7)
Liver disease 5 (16.1)
Chronic renal disease 3 (9.7)
Exam Cachexia, malnourishment, or wasting 5 (18.5)
Fever ≥100.5°F (38°C) 25 (80.6)
Rash 13 (41.9)
Altered mental status or comatose 9 (31.0)
Complications ICU admission 16 (55.2)
Respiratory failure requiring intubation 8 (25.0)
Purpura fulminans 1 (3.1)
Waterhouse-Friederichsen syndrome 1 (3.1)
Death 4 (12.1)
HIV-related clinical datab
CDC AIDS surveillance case definition met 18 (56.3)
History of AIDS-defining condition only 8 (44.4)
History of CD4 ever <200 cells/µL only 6 (33.3)
Both AIDS-defining condition and CD4 criteria met 4 (22.2)
Concurrent CD4 count available 22 (68.8)
≥500 cells/µL 7 (31.8)
200–499 cells/µL 9 (40.9)
<200 cells/µL 6 (27.3)
History of HAART use ascertainable 25 (78.1)
Currently taking at time of presentation 16 (64.0)
Previous use 7 (28.0)
Never used 2 (8.0)
Currently taking opportunistic infection  
prophylaxis at time of presentationc
7 (22.6)
Abbreviations: AIDS, acquired immune deficiency syndrome; CDC, Centers for Disease 
Control and Prevention; HAART, highly active antiretroviral therapy; HIV, human immunode-
ficiency virus; ICU, intensive care unit.
aDenominators may vary due to missing data.
bReported data on CD4 percentages and HIV viral load testing was limited and are not shown.
cDefined as taking trimethoprim-sulfamethoxazole, azithromycin, dapsone, or other med-
ication specifically for prophylaxis against Pneumocystis pneumonia or Mycobacteriam 
avium complex infection.
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reported AIDS-defining condition alone. Twenty-two persons 
with HIV had a concurrent CD4 count available, with 6 persons 
(27.3%) having a CD4 count less than 200 cells/µL. Data on HIV 
viral loads, CD4 percentages, and CD4 count nadir history were 
limited (data not shown). The case fatality ratios were similar 
among HIV-infected patients who met the CDC AIDS surveil-
lance criteria and those who did not (11.1% vs 14.3%, P = .8).
A total of 491 cases of meningococcal disease among persons 
aged 25 to 64 were reported to ABCs from study sites, 17 of 
whom had HIV infection that met the CDC AIDS surveillance 
case definition. The mean number of persons living with HIV 
infection ever classified as AIDS in this age group each year dur-
ing 2000 to 2008 in the included ABCs sites was 53 212, result-
ing in a cumulative, mean incidence of 3.5 cases per 100 000 
person years (95% CI, 2.1–5.6) for meningococcal disease 
among persons reported with AIDS. The incidence of menin-
gococcal disease among the population not reported with AIDS 
(ie, patients with meningococcal disease without HIV reported 
or patients with HIV infection that did not meet the AIDS sur-
veillance case definition based on chart review) was 0.3 cases 
per 100 000 person years (95% CI, .3–.3), resulting in a rate ratio 
of 12.9 (95% CI, 7.9–20.9) of meningococcal disease among 
persons with infection meeting the AIDS surveillance case defi-
nition. The rate ratio among men (11.8; 95% CI, 6.7–20.6) was 
not significantly different from that among women (15.1; 95%, 
CI 5.6–40.6; P > .05 for the comparison). The rate ratio among 
persons aged 25–44 years (12.5; 95% CI, 6.8–25.6) was similar 
to that among those aged 45–64 (13.2; 95% CI, 6.2–25.2).
Ten of the seventeen meningococcal disease patients aged 25 
to 64 with HIV infection meeting the AIDS surveillance case 
definition had a report of a CD4 count <200 cells/µL. When 
including only these patients as cases of meningococcal dis-
ease among persons reported to have AIDS (and considering 
the excluded 7 cases as cases of meningococcal disease among 
those not reported with AIDS), the mean incidence of menin-
gococcal disease among persons reported with AIDS was 2.1 
cases per 100 000 person years (95% CI, 1.1–3.7), resulting in 
a rate ratio of 7.5 (95% CI, 4.0–14.0) when compared with the 
incidence of meningococcal disease among the population aged 
25 to 64 years that were not reported with AIDS.
DISCUSSION
We found a substantially increased risk of meningococcal dis-
ease among adults with HIV infection that met AIDS surveil-
lance criteria, compared with all other individuals not reported 
with AIDS. The clinical presentations and outcomes of menin-
gococcal disease in these patients were generally similar to 
those in patients without HIV infection, and patients presented 
with a wide range of CD4 counts. Because the incidence of 
meningococcal disease in the United States has decreased sig-
nificantly over the past decade [19], and the prevalence of HIV 
infection in the United States in recent years is estimated to 
be less than 500 per 100 000 persons [20], the total number of 
meningococcal disease cases among persons living with HIV is 
likely low. Because not all ABCs sites had name-based HIV case 
reporting during the period considered for this evaluation and 
not all persons with HIV have been diagnosed and reported, 
we were not able to estimate an incidence of meningococcal 
disease among all persons with HIV infection. For our calcula-
tion of incidence, we included those living with HIV infection 
ever classified as AIDS, which includes persons with immune 
reconstitution; therefore, it is important to emphasize that our 
incidence estimate applies to a patient population with varia-
ble levels of immunocompetence. Although this population is 
not necessarily representative of the larger population of per-
sons living with HIV infection, the increased relative risk we 
observed for meningococcal disease is similar to those observed 
for HIV-infected individuals in New York City, South Africa, 
and England [11–13].
In this study, almost half of the patients with meningococcal 
disease and HIV infection that met AIDS surveillance criteria 
did not have a CD4 cell count history available and were staged 
only with a history of an AIDS-defining condition. Because the 
majority of persons included in the US HIV surveillance sys-
tem are staged with immunologic (CD4 count) criteria rather 
than an AIDS-defining condition history [18], we considered 
the possibility that our meningococcal disease incidence calcu-
lation might be inflated by the incongruous patterns of criteria 
used in staging. To address this possibility, we calculated the 
incidence of meningococcal disease among those reported with 
AIDS including only patients with HIV infection and a history 
of a CD4 cell count <200 cells/µL in the numerator. Although 
the incidence calculated was lower, the rate ratio was still ele-
vated (7.5) when compared with the incidence of meningococ-
cal disease in the population not reported with AIDS.
Our study is subject to other limitations. A patient’s HIV sta-
tus may not have been known to the treating physician. Among 
the patients with HIV infection reported in ABCs, many inpa-
tient medical records had incomplete CD4 count histories (ie, 
current counts or nadir count), and the history of previous 
opportunistic infections is likely also incomplete. Therefore, 
our ascertainment of patients with HIV infection meeting CDC 
AIDS surveillance criteria is presumably incomplete. It should 
also be noted that the AIDS surveillance case definition used 
by the CDC during the period of this study included a subset 
of cases without laboratory-confirmed HIV infection [21]. 
The above factors would bias our estimates towards an under-
estimate of meningococcal disease risk in persons with HIV 
meeting AIDS surveillance criteria. On the other hand, any 
incomplete ascertainment of persons with HIV infection meet-
ing the AIDS surveillance criteria in the general population 
would bias our estimates of meningococcal disease risk in this 
population towards an overestimate.
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We were unable to control for possible confounding due to 
smoking, which is an established risk factor for meningococcal 
disease, due to limited tobacco use history reported in the ABCs 
surveillance system during the study period. Smoking preva-
lence among HIV-infected individuals has been described to 
be as much as 3 times the prevalence in the general population 
[22]. The risk of meningococcal disease among smokers is 2–3 
times the risk among nonsmokers [23]. Further study may help 
elucidate the portion of the increased risk for meningococcal 
disease among HIV-infected persons that might be attributable 
to smoking or other risk factors associated with meningococcal 
disease.
This study is limited to patients reported during 2000 through 
2008; therefore, our findings do not reflect any changes in dis-
ease epidemiology since 2008. It is noteworthy to mention that 
since 2012, there have been multiple reports of meningococcal 
disease clusters among men who have sex with men (MSM) 
[24, 25]. Among cases in MSM where HIV status was known, as 
many as 59% of patients were HIV-infected [24]. In our study, 
data on MSM status were not collected in our expanded chart 
review or the standard ABCs case report form.
CONCLUSIONS
In summary, we observed an increased incidence of meningo-
coccal disease among patients with HIV ever classified as AIDS 
in the United States. Our findings are consistent with those of 
other population-based studies that have shown an increased 
incidence of meningococcal disease among HIV-infected per-
sons [11–13]. Considering these studies, in June 2016 the US 
Advisory Committee on Immunization Practices approved a 
recommendation for routine vaccination of HIV-infected per-
sons aged ≥2 months [26].
Acknowledgments
We thank the Active Bacterial Core surveillance system surveillance 
officers of the Centers for Disease Control and Prevention (CDC) Emerging 
Infections Program; Tracy Pondo of the Division of Bacterial Diseases, 
National Center for Immunization and Respiratory Diseases (CDC); and 
David Stephens of the Division of Infectious Diseases, Emory University 
School of Medicine.
Disclaimer. The findings and conclusions in this article are those of 
the authors and do not necessarily represent the views of the Centers for 
Disease Control and Prevention.
Financial support. This work was funded by the Centers for Disease 
Control and Prevention Emerging Infections Program cooperative agree-
ment (Grant CI05-026), which funded Active Bacterial Core surveillance 
system sites.
Potential conflicts of interest. All authors: No reported conflicts. 
All authors have submitted the ICMJE Form for Disclosure of Potential 
Conflicts of Interest.
References
1. Klugman KP, Madhi SA, Feldman C. HIV and pneumococcal disease. Curr Opin 
Infect Dis 2007; 20:11–5.
2. Price VE, Blanchette VS, Ford-Jones EL. The prevention and management of 
infections in children with asplenia or hyposplenia. Infect Dis Clin North Am 
2007; 21:697–710, viii–ix.
3. Figueroa JE, Densen P. Infectious diseases associated with complement deficien-
cies. Clin Microbiol Rev 1991; 4:359–95.
4. Stephens DS, Hajjeh RA, Baughman WS, et al. Sporadic meningococcal disease 
in adults: results of a 5-year population-based study. Ann Intern Med 1995; 
123:937–40.
5. Couldwell DL. Invasive meningococcal disease and HIV coinfection. Commun 
Dis Intell Q Rep 2001; 25:279–80.
6. Pearson IC, Baker R, Sullivan AK, et al. Meningococcal infection in patients with 
the human immunodeficiency virus and acquired immunodeficiency syndrome. 
Int J STD AIDS 2001; 12:410–1.
7. Brindle R, Simani P, Newnham R, et al. No association between meningococcal 
disease and human immunodeficiency virus in adults in Nairobi, Kenya. Trans R 
Soc Trop Med Hyg 1991; 85:651.
8. Gilks CF, Brindle RJ, Otieno LS, et al. Life-threatening bacteraemia in HIV-1 sero-
positive adults admitted to hospital in Nairobi, Kenya. Lancet 1990; 336:545–9.
9. Kipp W, Kamugisha J, Rehle T. Meningococcal meningitis and HIV infection: 
results from a case-control study in western Uganda. AIDS 1992; 6:1557–8.
10. Pinner RW, Onyango F, Perkins BA, et  al. Epidemic meningococcal disease in 
Nairobi, Kenya, 1989. The Kenya/Centers for Disease Control (CDC) Meningitis 
Study Group. J Infect Dis 1992; 166:359–64.
11. Cohen C, Singh E, Wu HM, et al. Increased incidence of meningococcal disease 
in HIV-infected individuals associated with higher case-fatality ratios in South 
Africa. AIDS 2010; 24:1351–60.
12. Miller L, Arakaki L, Ramautar A, et al. Elevated risk for invasive meningococcal 
disease among persons with HIV. Ann Intern Med 2014; 160:30–7.
13. Simmons RD, Kirwan P, Beebeejaun K, et  al. Risk of invasive meningococcal 
disease in children and adults with HIV in England: a population-based cohort 
study. BMC Med 2015; 13:297.
14. Schuchat A, Hilger T, Zell E, et al. Active bacterial core surveillance of the emerg-
ing infections program network. Emerg Infect Dis 2001; 7:92–9.
15. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance 
(ABCs). Available at: http://www.cdc.gov/abcs/index.html. Accessed October 6, 
2016.
16. Mothershed EA, Sacchi CT, Whitney AM, et al. Use of real-time PCR to resolve 
slide agglutination discrepancies in serogroup identification of Neisseria mening-
itidis. J Clin Microbiol 2004; 42:320–8.
17. Selik RM, Mokotoff ED, Branson B, et al. Revised surveillance case definition for 
HIV infection–United States, 2014. MMWR Morb Mortal Wkly Rep 2014; 63:1–10.
18. CDC. Reported CD4+ T-lymphocyte and viral load results for adults and adoles-
cents with HIV infection–37 states, 2005–2007. HIV Surveillance Supplemental 
Report 2011; 16.
19. Centers for Disease Control and Prevention. Meningococcal disease. In: 
Hamborsky J, Kroger A, Wolfe S (eds). Epidemiology and Prevention of Vaccine-
Preventable Diseases. 13th ed. Washington, D.C.: Public Health Foundation, 2015: 
pp 231–46.
20. CDC. Monitoring selected national HIV prevention and care objectives by 
using HIV surveillance data–United States and 6 dependent areas–2013. HIV 
Surveillance Supplemental Report 2015; 20.
21. Schneider E, Whitmore S, Glynn KM, et al. Revised surveillance case definitions 
for HIV infection among adults, adolescents, and children aged <18 months and 
for HIV infection and AIDS among children aged 18 months to <13 years–United 
States, 2008. MMWR Morb Mortal Wkly Rep 2008; 57(RR-10):1–12.
22. Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV pos-
itive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS 
Behav 2010; 14:824–35.
23. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for menin-
gococcal disease. Pediatr Infect Dis J 1997; 16:979–83.
24. Kamiya H, MacNeil J, Blain A, et  al. Meningococcal disease among men who 
have sex with men - United States, January 2012-June 2015. MMWR Morb Mortal 
Wkly Rep 2015; 64:1256–7.
25. Nanduri S, Foo C, Ngo V, et al. Outbreak of serogroup c meningococcal disease 
primarily affecting men who have sex with men—Southern California, 2016. 
MMWR Morb Mortal Wkly Rep 2016; 65:939–40.
26. MacNeil JR, Rubin LG, Patton M, Ortega-Sanchez IR, Martin SW. 
Recommendations for use of meningococcal conjugate vaccines in HIV-infected 
persons—Advisory Committee on Immunization Practices, 2016. MMWR Morb 
Mortal Wkly Rep 2016;65:1189–1194. doi:10.15585/mmwr.mm6543a3. Available 
at: http://www.cdc.gov/mmwr/volumes/65/wr/mm6543a3.htm.
